The LRRK2 R1628P variant plays a protective role in han chinese population with alzheimer's disease

CNS Neuroscience and Therapeutics

Volumn 19, Issue 4, 2013, Pages 207-215

  Li, Hong Lei ^a   Lu, Shen Ji ^a   Sun, Yi Min ^a   Guo, Qi Hao ^a   Sadovnick, Adele Dessa ^b   Wu, Zhi Ying ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Association; Chinese; LRRK2

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; LEUCINE RICH REPEAT KINASE 2;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPORADIC ALZHEIMER DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES;

EID: 84875576591     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12062     Document Type: Article

References (27)

1. Clarimon J, Djaldetti R, Lleo A, et al. Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. Neurobiol Aging 2009;30:1986-1991.
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
4. Marder K, Tang MX, Alfaro B, et al. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999;52:719-724.
5. Hofman A, Schulte W, Tanja TA, et al. History of dementia and Parkinson's disease in 1st-degree relatives of patients with Alzheimer's disease. Neurology 1989;39:1589-1592.
6. Papapetropoulos S, Lieberman A, Gonzalez J, Mash DC. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand 2005;111: 353-359.
7. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
8. Zabetian CP, Samii A, Mosley AD, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 2005;65:741-744.
9. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997;278:1237-1241.
10. Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009;84:35-43.
11. Li HL, Shi SS, Guo QH, et al. PICALM and CR1 variants are not associated with sporadic Alzheimer's disease in Chinese patients. J Alzheimers Dis; 25: 111-117.
12. Donohoe GG, Salomaki A, Lehtimaki T, Pulkki K, Kairisto V. Rapid identification of apolipoprotein E genotypes by multiplex amplification refractory mutation system PCR and capillary gel electrophoresis. Clin Chem 1999;45:143-146.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Miklossy J, Arai T, Guo JP, et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 2006;65:953-963.
15. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 2008;86:1711-1720.
16. Gillardon F. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 2009;163:533-539.
17. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 2009;110:1514-1522.
18. Lin TK, Liou CW, Chen SD, et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med J 2009;32:589-599.
19. Santos-Reboucas CB, Abdalla CB, Martins PA, et al. LRRK2 p.G2019S mutation is not common among Alzheimer's disease patients in Brazil. Dis Markers 2009;27: 13-16.
20. Tedde A, Bagnoli S, Cellini E, Nacmias B, Piacentini S, Sorbi S. No association between the LRRK2 G2019S mutation and Alzheimer's disease in Italy. Cell Mol Neurobiol 2007;27:877-881.
21. Chang TY, Kuo HC, Lu CS, Wu-Chou YH, Huang CC. Analysis of the LRRK2 Gly2385Arg variant in Alzheimer's disease in Taiwan. Parkinsonism Relat Disord;16: 28-30.
22. Tan EK, Lee J, Chen CP, Wong MC, Zhao Y. Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. Neurobiol Aging 2009;30:501-502.
23. Saunders-Pullman R, Lipton RB, Senthil G, et al. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 2006;402:92-96.
24. Lee E, Hui S, Ho G, Tan EK, Chen CP. LRRK2 G2019S and I2020T mutations are not common in Alzheimer's disease and vascular dementia. Am J Med Genet B Neuropsychiatr Genet 2006;141B:549-550.
25. Toft M, Sando SB, Melquist S, et al. LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 2005;126:1201-1205.
26. Zhao Y, Ho P, Yih Y, Chen C, Lee WL, Tan EK. LRRK2 variant associated with Alzheimer's disease. Neurobiol Aging 2011;32:1990-1993.
27. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272-1276.